Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its glucose monitoring products, the G6 and G7, which could pose health risks to users [1]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable than previous versions [1]. - It is claimed that these changes presented a material health risk to users who depend on these devices for accurate glucose readings [1]. - The lawsuit asserts that the enhancements to the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [1]. - The defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [1]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [1]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Integer Holdings Corporation regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and sales performance in the electrophysiology manufacturing market [1][2]. Group 1: Allegations - The complaint alleges that Integer Holdings Corporation overstated its competitive position within the electrophysiology manufacturing market [1]. - It is claimed that despite the company's assertions of strong visibility into customer demand, there was a sustained deterioration in sales for two of its electrophysiology devices [1]. - The company mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to misleading positive statements about its business and operations [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as July 25, 2024, to October 22, 2025 [1]. - Shareholders are encouraged to register for the class action by February 9, 2026, to potentially be appointed as lead plaintiffs [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Insights - SAFE sponsored the 12th MAMMI International Meeting focused on Diagnosis and Minimally Invasive Treatment of the Spine, held in Cagliari from December 9 to 11, 2025 [1][4] - The event featured international experts discussing advancements in minimally invasive spine treatment, including live surgical demonstrations [2][3] Company Overview - Safe Group is a French medical technology group that includes Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical, a subcontractor for orthopedic surgeries [5] - The group employs approximately 100 people and has subsidiaries in the United Kingdom, Germany, and the United States [6] Technology and Innovation - Safe Orthopaedics develops and manufactures SteriSpineTM kits, which combine sterile implants and ready-to-use instruments, aimed at minimizing contamination and infection risks [6] - The technology is protected by 15 patent families and is CE marked and FDA approved, contributing to reduced hospitalization times and costs [6] Event Significance - The MAMMI meeting is recognized as a key event for professionals in minimally invasive spinal surgery, facilitating knowledge sharing and innovation in the field [4]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the launch and demand for its Inspire V device, leading to significant financial losses for investors [3][5]. Group 1: Allegations and Legal Action - The complaint against Inspire Medical Systems claims that the company and its executives violated federal securities laws by making false or misleading statements about the market demand for the Inspire V device and the steps taken for its launch [3]. - Investors are reminded of the January 5, 2026 deadline to seek the role of lead plaintiff in the class action lawsuit [1][6]. Group 2: Launch Issues and Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [4]. - The company reported weak demand and excess inventory for the Inspire V, leading to a more than 80% cut in its 2025 earnings guidance [5]. - Following these announcements, Inspire's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [5].

Core Insights - Enovis Corporation (NYSE:ENOV) is identified as a promising small-cap stock with significant upside potential, despite recent adjustments to price targets by analysts [1][2] - The company is experiencing a rebound in organic growth, particularly in 2025, with expectations for continued momentum [2][3] - Enovis reported a 9% increase in net sales for fiscal Q3 2025, reaching $549 million, driven by stable end markets and successful new product introductions [4] Analyst Ratings and Price Targets - Canaccord Genuity reduced its price target for Enovis to $50 from $58 while maintaining a Buy rating, reflecting updated 2027 estimates [1] - Freedom Capital initiated coverage with a Buy rating and set a price target of $45, highlighting the company's improving competitive positioning [2][3] Financial Performance - In fiscal Q3 2025, Enovis's net sales rose 9% on a reported basis and 7% on an organic basis compared to the previous year [4] - The Reconstructive segment saw a 2% increase in reported sales and a 9% increase in organic sales, while the Prevention & Recovery segment grew 6% on a reported basis and 4% organically [4] Company Overview - Enovis Corporation is a medical technology growth company focused on developing clinically differentiated solutions aimed at improving workflows and patient outcomes [5]

Boston Scientific Corporation (NYSE:BSX) is one of the 14 Best Large Cap Stocks to Invest In Now. On December 17, UBS reiterated its Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept the price target at $140. This update comes even as the shares experienced a drop over the past month. UBS analyst Danielle Antalffy believes that the risk/reward profile for Boston Scientific Corporation (NYSE:BSX) is “increasingly skewed to the upside” heading into 2026. This view is supported by the firm’s op ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer announced a reduction in its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6] - The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, alongside slower adoption rates for two of its EP devices [6] - Following this announcement, Integer's stock price plummeted by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

Market Overview - The market has experienced volatility, likened to the "Three Stooges," with tech stocks fluctuating significantly due to AI developments and inflation data [2][3] - The Consumer Price Index (CPI) indicated positive inflation trends, but concerns about data accuracy arose due to the government shutdown [3] - Unemployment rose to 4.6%, but this figure may be overstated, suggesting a more favorable employment situation [3] Job Market Insights - Jobless claims have shown a slight dip, providing a reliable indicator amidst other fluctuating data [4] - The overall market sentiment suggests a flat trajectory for December, with alternating good and bad news days expected [5] IPO Market Developments - Medline's IPO was the largest of the year, raising over $6 billion and marking the biggest IPO since Rivian in 2021, with a stock price increase of 40% [6] - Anticipation surrounds SpaceX's potential IPO, with speculation about a valuation of $1.5 trillion, although no timeline has been established [7][8] Cannabis Industry Updates - The signing of an executive order by President Trump reclassifies marijuana from a Schedule I to a Schedule III drug, allowing companies to deduct business expenses, potentially boosting cash flows by up to $150 million [11][12][13] - Despite initial stock price increases, marijuana stocks experienced a decline following the executive order, indicating a "buy the rumor, sell the news" scenario [11][14] - Many cannabis companies are involved in both farming and distribution, which may impact their operational strategies moving forward [15]

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [3]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing health risks to users relying on accurate glucose readings [3]. - DexCom is accused of overstating the enhancements and reliability of the G7 device while downplaying the severity of issues related to adulterated devices [3]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [3]. Group 2: Legal Process and Representation - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiffs in the class action [4]. - A lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [4]. - Investors can choose to remain absent from the proceedings without affecting their ability to share in any recovery [4].